Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroendocrine Tumors 3Lung Neoplasms 2Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Pancreatic Ductal Adenocarcinoma 1Neural crest tumor 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Liver Neoplasms 1Liver Malignancy 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1Breast Neoplasms 1Bile Duct Neoplasms 1

Interventions

Gemcitabine 2130-nm albumin-bound paclitaxel 2tislelizumab 1lenvatinib 1ivosidenib 1Positron Emission Tomography Computed Tomography 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Pancreatic Ductal Adenocarcinoma × Positron Emission Tomography Computed Tomography × Clear all
NCT03851237 2026-05-08

CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy

Washington University School of Medicine

Phase 1 Completed
69 enrolled
Gastrointestinal

Pancreatic Ductal Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡